New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...

The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

Patients recently diagnosed with cancer show an increased risk for major bleeding after myocardial infarction, with the risk ...

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...

James Stewart puts on his rollerblades to get ready to do the trail in Rabb Park on his day off. He continues to be able to be active because of a new treatment for bladder cancer. Last year, at 39, ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, ...

BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious ...

CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that utilizes artificial intelligence ...